Zevra Therapeutics to be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024

Core Points - Zevra Therapeutics, Inc. will be added to the Nasdaq Biotechnology Index effective December 23, 2024, which is part of the annual reconstitution of the Nasdaq indexes [1] - The addition to the Nasdaq Biotechnology Index is expected to enhance Zevra's visibility among biotech funds and portfolio managers, reflecting a transformational year for the company [2] Company Overview - Zevra Therapeutics is a commercial-stage company focused on developing therapies for rare diseases, aiming to address unmet medical needs [5] - The company employs unique, data-driven strategies for drug development and commercialization to overcome challenges in bringing new therapies to the rare disease community [5] Index Information - The Nasdaq Biotechnology Index tracks the performance of securities classified as biotechnology or pharmaceutical, calculated using a modified capitalization-weighted methodology [3] - Companies must meet specific eligibility criteria, including minimum market capitalization and average daily trading volume, to be included in the index [3]